參考文獻/References:
[1] FUKAZAWA R,KOBAYASHI J,AYUSAWA M,et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J].Circ J,2020,84(8): 1348-1407.
[2] 閆輝,杜軍保.川崎病的臨床診治探索任重道遠[J].中國實用兒科雜志,2017,32(8):561-564.
[3] 王雷,夏焙.超聲心動圖在川崎病診斷、治療及長期隨訪中的應用進展——2017年AHA指南的解讀[J/CD].中華醫(yī)學超聲雜志(電子版),2019,16(3):161-165.
[4] 中華醫(yī)學會兒科學分會心血管病學組,《中華兒科雜志》編輯委員會.川崎病冠狀動脈病變的臨床處理建議(2020年修訂版)[J].中華兒科雜志,2020,58(9):718-724.
[5] McCRINDLE B W,ROWLEY A H,NEWBURGER J W,et al. Diagnosis,treatment,and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J].Circulation,2017,135(17): e927-e999.
[6] DALLAIRE F,DAHDAH N. New equations and a critical appraisal of coronary artery Z scores in healthy children[J].J Am Soc Echocardiogr,2011,24(1): 60-74.
[7] YOKOTA S,KIKUCHI M,NOZAWA T,et al. Pathoge-nesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease,systemic onset juvenile idiopathic arthritis,and cryopyrin-associated periodic fever syndrome"[J].Modern Rheumatology,2015,25(1): 1-10.
[8] 范雪,徐明國.川崎病發(fā)病機制及治療研究進展[J].中國實用兒科雜志,2021,36(5):339-344.
[9] 黃宏琳,黃育坤,林淑斌,等.TNF-α、IL-1β及IL-6 水平用于評估川崎病患兒發(fā)生冠狀動脈損傷的臨床價值[J].中國醫(yī)學創(chuàng)新,2020,17(4):12-15.
[10] 彭珍,閆孝永.ACEF評分聯(lián)合炎性因子評估小兒川崎病冠狀動脈損害的臨床價值[J].中西醫(yī)結合心腦血管病雜志,2022,20(16):3016-3020.
[11] KIM M K,SONG M S,KIM G B. Factors predicting re-sistance to intravenous immunoglobulin treatment and coronary artery lesion in patients with Kawasaki disease:analysis of the Korean nationwide multicenter survey from 2012 to 2014[J].Korean Circ J,2018,48(1):71-79.
[12] RIFE E,GEDALIA A. Kawasaki disease: An update[J].Curr Rheumatol Rep,2020,22(10):75.
[13] SAMADLI S,LIU F F,MAMMADOV G,et al. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease[J].Pediatr Rheumatol Online J,2019,17(1):53.
[14] 王遠飛,李培嶺,田運嬌,等.川崎病合并中小型冠狀動脈瘤持續(xù)時間危險因素分析[J].中華實用兒科臨床雜志,2022,37(11): 816-820.
[15] 戈海延,曲東,劉霜,等. 6月齡以下嬰兒川崎病冠狀動脈病變的臨床特征及預后分析[J].中國小兒急救醫(yī)學,2022,29(3):206-210.